Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk to acquire obesity drug developer Inversago
03:56am, Thursday, 10'th Aug 2023
Danish drug maker Novo Nordisk said on Thursday it would acquire Canadian company Inversago Pharma in a $1.07 billion deal including the development of an appetite regulator.
Novo Nordisk, now Europe's second-largest company by market cap, lifts outlook after 46% profit rise
03:52am, Thursday, 10'th Aug 2023
Novo Nordisk, the Danish drugmaker that's now the second-largest company in Europe by market capitalization, on Thursday reported a 46% rise in profit and lifted its outlook for the year.
Wegovy-maker Novo Nordisk sales soar 30% on strong demand for its weight-loss drug
02:07am, Thursday, 10'th Aug 2023
The Danish company's diabetes and obesity division performed particularly well, bolstered by interest in its blockbuster injections Wegovy and Ozempic.
Novo Nordisk hikes FY outlook as demand for weight-loss drug Wegovy soars
01:42am, Thursday, 10'th Aug 2023
Danish drugmaker Novo Nordisk on Thursday hiked its full-year profit and sales forecast for a second time as its weight-loss and diabetes drugs flew off the shelves in the United States.
Fmr. FDA Commissioner Dr. Scott Gottlieb on diabetes drugs: Overall it's being used appropriately
11:09am, Wednesday, 09'th Aug 2023
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the growing interest in new diabetes drugs, with some showing promise for weight loss and heart disease prevention, the promise
Novo Nordisk Soars To New High On Weight-Loss Drug Trial Results
08:41am, Wednesday, 09'th Aug 2023
Weight-loss drugs are the pharmaceutical industry's equivalent of AI, in the sense of being a product with the capability to send shares soaring. Novo Nordisk A/S NYSE: NVO, maker of Wegovy, saw its s
Weight loss injections 'can lower heart attack and stroke risk by a fifth'
04:33pm, Tuesday, 08'th Aug 2023
Weight loss injections can lower the risk of a heart attack or stroke in obese people with cardiovascular disease by a fifth, a new study has suggested.
Novo Nordisk weight loss drug Wegovy cuts heart disease risk by 20%, trial shows
02:31pm, Tuesday, 08'th Aug 2023
Novo Nordisk said the results of a late-stage drug trial showed weight loss drug Wegovy also can cut the risk of heart disease in certain patients.
Weight-Loss Drug Frenzy Drives Eli Lilly And Novo Nordisk Stock To Record Highs
01:51pm, Tuesday, 08'th Aug 2023
Shares of Eli Lilly and Novo Nordisk both soared to record highs on Tuesday, as sales increased of Eli Lilly's Mounjaro and as Novo Nordisk reports a promising clinical trial of its drug Wegovy.
Markets Plunge at Midday After Bank Downgrades
01:25pm, Tuesday, 08'th Aug 2023
U.S. equities sank at midday on Tuesday, Aug. 8, 2023, following bank downgrades by Moody's and data showing credit card debt rose to a record.
Novo Nordisk A/S: A Biotech Giant with High Outperformance Potential
12:58pm, Tuesday, 08'th Aug 2023
Novo Nordisk A/S ( NVO , Financial), a leading player in the biotechnology industry, has been making waves in the stock market. As of August 8, 2023, the company's stock price stands at $190.22, with
Novo Nordisk ADRs Surge After Wegovy Shown to Reduce Heart Attack, Stroke Risks
12:56pm, Tuesday, 08'th Aug 2023
ADRs of Novo Nordisk surged to an all-time high after a study found Novo Nordisk's Wegovy weight-loss drug also helped cut risk of major adverse cardiovascular events by 20%.
Novo weight-loss drug Wegovy shows heart benefit in trial
12:26pm, Tuesday, 08'th Aug 2023
The trial showed that patients on Wegovy had a 20% lower incidence of heart attack, stroke or death from heart disease compared to those on a placebo, Novo said.
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Are On Fire Today
11:45am, Tuesday, 08'th Aug 2023
Novo Nordisk's popular weight loss drug significantly reduced the risk of heart attack or stroke in a late-stage trial. These data bode well for the obesity drug category at large.
The Obesity Drug Revolution Just Got Real
10:24am, Tuesday, 08'th Aug 2023
New data show Novo Nordisk's Wegovy reduces risk of heart attack and stroke, paving the way for greater insurance coverage.
